Contrast-enhanced sonography of nonfunctioning pancreatic neuroendocrine tumors

American Journal of Roentgenology

Volumn 192, Issue 2, 2009, Pages 424-430

  Malagò, Roberto ^a   D'Onofrio, Mirko ^a   Zamboni, Giulia A ^a   Faccioli, Niccolò ^a   Falconi, Massimo ^a   Boninsegna, Letizia ^a   Mucelli, Roberto Pozzi ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Contrast enhanced sonography; Nonfunctioning endocrine tumor; Pancreas; Prognosis

Indexed keywords

KI 67 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; B SCAN; CANCER DIAGNOSIS; CANCER GRADING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL STUDY; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; ECHOGRAPHY; FEMALE; HOMOGENATE; HUMAN; LIVER INJURY; LIVER METASTASIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MITOSIS INDEX; NEUROENDOCRINE TUMOR; NEUROENDOCRINOLOGY; PANCREAS ISLET CELL TUMOR; PATHOLOGY; PHASE CONTRAST MICROSCOPY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLID; TUMOR LOCALIZATION; VASCULAR LESION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PHOSPHOLIPIDS; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SULFUR HEXAFLUORIDE; TUMOR MARKERS, BIOLOGICAL; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 59349101366     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.4043     Document Type: Article

References (38)

1. Rindi G, Capella C, Solcia E. Cell biology, clinicopathological profile, and classification of gastroenteropancreatic endocrine tumors. J Mol Med 1998; 76:413-420
2. Ros PR, Mortelé KJ. Imaging features of pancreatic neoplasms. JBR-BTR 2001; 84:239-249
3. Chang S, Choi D, Lee SJ, et al. Neuroendocrine neoplasms of the gastrointestinal tract: classification, pathologic basis, and imaging features. RadioGraphics 2007; 27:1667-1679
4. Tomassetti P, Campana D, Piscitelli L, et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005; 16:1806-1810
5. Frankel WL. Update on pancreatic endocrine tumors. Arch Pathol Lab Med 2006; 130:963-966
6. Dromain C, Baudin E. Endocrine pancreas. J Radiol 2005; 86:797-804
7. Capella C, Heitz PU, Höfler H, Solcia E, Klöppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995; 425:547-560
8. Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395-401
9. Ferrari L, Seregni E, Lucignani G, et al. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors. Int J Biol Markers 2004; 19:295-304
10. Stanton KJ, Sidner RA, Miller GA, et al. Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg 2003; 186:486-492
11. Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy - a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996; 27:1124-1134
12. Pereira PL, Wiskirchen J. Morphological and functional investigations of neuroendocrine tumors of the pancreas. Eur Radiol 2003; 13:2133-2146
13. Goto A, Niki T, Terado Y, Fukushima J, Fukayama M. Prevalence of CD99 protein expression in pancreatic endocrine tumours (PETs). Histopathology 2004; 45:384-392
14. Mao C, Carter P, Schaefer P, et al. Malignant islet cell tumor associated with hypercalcemia. Surgery 1995; 117:37-40
15. Eckhauser FE, Cheung PS, Vinik AI, Strodel WE, Lloyd RV, Thompson NW. Nonfunctioning malignant neuroendocrine tumors of the pancreas. Surgery 1986; 100:978-988
16. Park BJ, Alexander HR, Libutti SK, et al. Operative management of islet-cell tumors arising in the head of the pancreas. Surgery 1998; 124:1056-1061
17. La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996; 429:323-333
18. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12:1083-1092
19. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007; 21:43-68
20. 111In] DTPA-octreotide scintigraphy (OctreoScan): a comparative study with CT and MR imaging. QJM 1998; 91:295-301
21. Procacci C, Carbognin G, Accordini S, et al. Non-functioning endocrine tumors of the pancreas: possibilities of spiral CT characterization. Eur Radiol 2001; 11:1175-1183
22. Imbriaco M, Megibow AJ, Ragozzino A, et al. Value of the single-phase technique in MDCT assessment of pancreatic tumors. AJR 2005; 184:1111-1117
23. Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/ carcinoma. Neuroendocrinology 2006; 84: 196-211
24. D'Onofrio M, Mansueto G, Falconi M, Procacci C. Neuroendocrine pancreatic tumor: value of contrast enhanced ultrasonography. Abdom Imaging 2004; 29:246-258
25. Ricke J, Hänninen EL, Amthauer H, Lemke A, Felix R. Assessment of the vascularization of neuroendocrine tumors by stimulated acoustic emission of SH U 508A ultrasound contrast agent and color or power Doppler sonography. Invest Radiol 2000; 35:253-259
26. D'Onofrio M, Mansueto G, Vasori S, Falconi M, Procacci C. Contrast-enhanced ultrasonographic detection of small pancreatic insulinoma. J Ultrasound Med 2003; 22:413-417
27. Rickes S, Mönkemüller K, Malfertheiner P. Contrast-enhanced ultrasound in the diagnosis of pancreatic tumors. JOP 2006; 7:584-592
28. Fugazzola C, Procacci C, Bergamo Andreis IA, et al. The contribution of ultrasonography and computed tomography in the diagnosis of nonfunctioning islet cell tumors of the pancreas. Gastrointest Radiol 1990; 15:139-144
29. Kitano M, Kudo M, Maekawa K, et al. Dynamic imaging of pancreatic diseases by contrast enhanced coded phase inversion harmonic ultrasonography. Gut 2004; 53:854-859
30. Gandolfi L, Torresan F, Solmi L, Puccetti A. The role of ultrasound in biliary and pancreatic diseases. Eur J Ultrasound 2003; 16:141-159
31. D'Onofrio M, Zamboni G, Faccioli N, Capelli P, Pozzi Mucelli R. Ultrasonography of the pancreas. Part 4. Contrast-enhanced imaging. Abdom Imaging 2007; 32:171-181
32. Quaia E, Degobbis F, Tona G, Mosconi E, Bertolotto M, Pozzi Mucelli R. Differential patterns of contrast enhancement in different focal liver lesions after injection of the microbubble US contrast agent SonoVue. Radiol Med 2004; 107:155-165
33. D'Onofrio M, Martone E, Faccioli N, Zamboni G, Malagò R, Pozzi Mucelli R. Focal liver lesions: sinusoidal phase of CEUS. Abdom Imaging 2006; 31:529-536
34. Schmitt AM, Anlauf M, Rousson V, et al. WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors. Am J Surg Pathol 2007; 31:1677-1682
35. De Lellis RA, Wolfe HJ. Contributions of immunohistochemistry to clinical endocrinology and endocrine pathology. J Histochem Cytochem 1983; 31:187-192
36. Quaia E, Stacul F, Gaiani S, et al. Comparison of diagnostic performance of unenhanced vs SonoVue-enhanced ultrasonography in focal liver lesions characterization: the experience of three Italian centers. Radiol Med 2004; 108:71-81
37. D'Onofrio M, Megibow AJ, Faccioli N, et al. Comparison of contrast-enhanced sonography and MRI in displaying anatomic features of cystic pancreatic masses. AJR 2007; 189:1435-1442
38. Yang W, Chen MH, Yan K, Wu W, Dai Y, Zhang H. Differential diagnosis of non-functional islet cell tumor and pancreatic carcinoma with sonography. Eur J Radiol 2007; 62:342-351